Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Feb 7;16(1):26.
doi: 10.1186/s12974-019-1419-2.

Co-inhibition of PGF and VEGF blocks their expression in mononuclear phagocytes and limits neovascularization and leakage in the murine retina

Affiliations

Co-inhibition of PGF and VEGF blocks their expression in mononuclear phagocytes and limits neovascularization and leakage in the murine retina

Carsten Balser et al. J Neuroinflammation. .

Abstract

Background: Age-related macular degeneration (AMD) is a leading cause of visual impairment in the elderly. The neovascular (wet) form of AMD can be treated with intravitreal injections of different anti-vascular endothelial growth factor (VEGF) agents. Placental growth factor (PGF) is another member of the VEGF family of cytokines with pro-angiogenic and pro-inflammatory effects. Here, we aimed to compare single and combined inhibition of VEGF-A and PGF in the laser-induced mouse model of choroidal neovascularization (CNV) with a focus on the effects on retinal mononuclear phagocytes.

Methods: CNV was induced in C57BL/6J mice using a YAG-Laser. Immediately after laser damage antibodies against VEGF-A (aVEGF), anti-PGF (aPGF), aVEGF combined with aPGF, aflibercept, or IgG control were injected intravitreally in both eyes. Three and 7 days after laser damage, the vascular leakage was determined by fluorescence angiography. Lectin staining of retinal and RPE/choroidal flat mounts was used to monitor CNV. In situ mRNA co-expression of Iba1, VEGF and PGF were quantified using in situ hybridization. Retinal and RPE/choroidal protein levels of VEGF and PGF as well as the pro-inflammatory cytokines IL-6, IL1-beta, and TNF were determined by ELISA.

Results: Early (day 3) and intermediate (day 7) vascular leakage and CNV were significantly inhibited by PGF and VEGF-A co-inhibition, most effectively with the trap molecule aflibercept. While VEGF-A blockage alone had no effects, trapping PGF especially with aflibercept prevented the accumulation of reactive microglia and macrophages in laser lesions. The lesion-related mRNA expression and secretion of VEGF-A and PGF by mononuclear phagocytes were potently suppressed by PGF and partially by VEGF-A inhibition. Protein levels of IL-6 and IL1-beta were strongly reduced in all treatment groups.

Conclusions: Retinal inhibition of PGF in combination with VEGF-A prevents vascular leakage and CNV possibly via modulating their own expression in mononuclear phagocytes. PGF-related, optimized strategies to target inflammation-mediated angiogenesis may help to increase efficacy and reduce non-responders in the treatment of wet AMD patients.

Keywords: Aflibercept; Age-related macular degeneration; Choroidal neovascularization; Laser CNV; Microglia; Neovascular AMD; Placental growth factor (PGF); Retinal degeneration; Vascular endothelial growth factor (VEGF).

PubMed Disclaimer

Conflict of interest statement

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

Thomas Langmann has participated in advisory boards from Bayer AG. All other authors declare no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Figures

Fig. 1
Fig. 1
Effects of PGF and VEGF inhibition on vascular leakage in fundus fluorescein angiography. a Representative fundus fluorescein angiography images of animals of the indicated treatment groups 3 and 7 days after laser-induced damage. b Quantification of vascular leakage by analyzing pixel intensities 3 days after laser-induced damage (n = 13 eyes for IgG, n = 14 eyes for aVEGF, n = 13 eyes for aPGF, n = 20 eyes for aVEGF/aPGF, n = 13 eyes for aflibercept). c Quantification of vascular leakage by analyzing pixel intensities 7 days after laser-induced damage (n = 26 eyes for IgG, n = 14 eyes for aVEGF, n = 14 eyes for aPGF, n = 16 eyes for aVEGF/aPGF, n = 27 eyes for aflibercept). d Quantification of vascular leakage area 3 days after laser-induced damage (n = 13 eyes for IgG, n = 14 eyes for aVEGF, n = 13 eyes for aPGF, n = 20 eyes for aVEGF/aPGF, n = 13 eyes for aflibercept). e Quantification of vascular leakage area 7 days after laser-induced damage (n = 26 eyes for IgG, n = 14 eyes for aVEGF, n = 14 eyes for aPGF, n = 16 eyes for aVEGF/aPGF, n = 27 eyes for aflibercept). Data are shown as mean ± SEM (*P < 0.05, **P < 0.01, ***P < 0.001)
Fig. 2
Fig. 2
Effects of PGF and VEGF inhibition on choroidal neovascularization. a Representative images of lectin-stained RPE/choroidal flat mounts of animals of all treatment groups 3 and 7 days after laser damage. Dashed lines indicate CNV areas, and the asterisks mark the optic nerve head. Scale bare: 100 μm. b Quantification of lectin-stained CNV areas in RPE/choroidal flat mounts 3 days after laser coagulation with ZEN software (n = 10 eyes for IgG, n = 10 eyes for aVEGF, n = 11 eyes for aPGF, n = 11 eyes for aVEGF/aPGF, n = 10 eyes for aflibercept). c Quantification of lectin-stained CNV areas in RPE/choroidal flat mounts 7 days after laser coagulation with ZEN software (n = 14 eyes for IgG, n = 13 eyes for aVEGF, n = 14 eyes for aPGF, n = 16 eyes for aVEGF/aPGF, n = 28 eyes for aflibercept). Data are shown as mean ± SEM (*P < 0.05, **P < 0.01, ***P < 0.001)
Fig. 3
Fig. 3
Effects of PGF and VEGF inhibition on microgliosis in retinal flat mounts. a Representative images of Iba1-stained microglia/macrophages in single laser spots of retinal flat mounts 3 and 7 days after laser coagulation. Scale bar: 100 μm. b Quantification of mononuclear phagocytes per laser spot in retinal flat mounts 3 days after laser-induced damage (n = 16 laser spots for IgG, n = 14 laser spots for aVEGF, n = 14 laser spots for aPGF, n = 15 laser spots for aVEGF/aPGF, n = 14 laser spots for aflibercept). c Quantification of mononuclear phagocytes per laser spot in retinal flat mounts 7 days after laser-induced damage (n = 14 laser spots for IgG, n = 14 laser spots for aVEGF, n = 15 laser spots for aPGF, n = 27 laser spots for aVEGF/aPGF, n = 28 laser spots for aflibercept). d Quantification of Iba1 signals 3 days after laser coagulation in retinal flat mounts by counting the mean of colored pixels per image (n = 16 laser spots for IgG, n = 14 laser spots for aVEGF, n = 14 laser spots for aPGF, n = 15 laser spots for aVEGF/aPGF, n = 14 laser spots for aflibercept). e Quantification of Iba1 signals 7 days after laser coagulation in retinal flat mounts by counting the mean of colored pixels per image (n = 14 laser spots for IgG, n = 14 laser spots for aVEGF, n = 15 laser spots for aPGF, n = 27 laser spots for aVEGF/aPGF, n = 28 laser spots for aflibercept). f Interleukin 6 (IL-6) levels in retinal flat mounts 6 h after laser damage quantified by ELISA (n = 8 flat mounts per group). Naive (not lasered) animals were used as controls. g Interleukin 1β (IL-1β) levels in retinal flat mounts 6 h after laser damage quantified by ELISA (n = 8 flat mounts per group). h Tumor necrosis factor (TNF) levels in retinal flat mounts 6 h after laser damage quantified by ELISA (n = 8 flat mounts per group). Data are shown as mean ± SEM (*P < 0.05, **P < 0.01, ***P < 0.001)
Fig. 4
Fig. 4
Effects of PGF and VEGF inhibition on mononuclear phagocytes in RPE/choroidal flat mounts. a Representative images of Iba1-stained microglia/macrophages in single laser spots of RPE/choroidal flat mounts 3 and 7 days after laser coagulation. Scale bar: 100 μm. b Quantification of mononuclear phagocytes per laser spot in retinal flat mounts 3 days after laser-induced damage (n = 20 laser spots for IgG, n = 10 laser spots for aVEGF, n = 12 laser spots for aPGF, n = 13 laser spots for aVEGF/aPGF, n = 27 laser spots for aflibercept). c Quantification of mononuclear phagocytes per laser spot in RPE/choroidal flat mounts 7 days after laser-induced damage (n = 11 laser spots for IgG, n = 10 laser spots for aVEGF, n = 10 laser spots for aPGF, n = 15 laser spots for aVEGF/aPGF, n = 30 laser spots for aflibercept). d Quantification of Iba1 signals 3 days after laser coagulation in RPE/choroidal flat mounts by counting the mean of colored pixels per image (n = 20 laser spots for IgG, n = 10 laser spots for aVEGF, n = 12 laser spots for aPGF, n = 13 laser spots for aVEGF/aPGF, n = 27 laser spots for aflibercept). e Quantification of Iba1 signals 7 days after laser coagulation in RPE/choroidal flat mounts by counting the mean of colored pixels per image (n = 11 laser spots for IgG, n = 10 laser spots for aVEGF, n = 10 laser spots for aPGF, n = 15 laser spots for aVEGF/aPGF, n = 30 laser spots for aflibercept). f Interleukin 6 (IL-6) levels in RPE/choroidal flat mounts 6 h after laser damage quantified by ELISA (n = 8 flat mounts per group). Naive (not lasered) animals were used as controls. g Interleukin 1β (IL-1β) levels in RPE/choroidal flat mounts 6 h after laser damage quantified by ELISA (n = 8 flat mounts per group). h Tumor necrosis factor (TNF) levels in RPE/choroidal flat mounts 6 h after laser damage quantified by ELISA (n = 8 flat mounts per group). Data are shown as mean ± SEM (*P < 0.05, **P < 0.01, ***P < 0.001)
Fig. 5
Fig. 5
Mononuclear phagocytes co-express PGF and VEGF mRNAs in laser lesions. Scale bar: 100 μm. a Representative images of in situ hybridization of single laser spots in RPE/choroidal flat mounts of IgG-treated animals at days 3 and 7. Probes targeted both Iba1 and VEGF. b Representative images of in situ hybridization of laser spots in RPE/choroidal flat mounts of IgG-treated animals at days 3 and 7. Probes targeted both Iba1 and PGF. c Representative images of in situ hybridization of laser spots in RPE/choroidal flat mounts of IgG-treated animals at days 3 and 7. Probes targeted both PGF and VEGF. The frames show higher magnification areas
Fig. 6
Fig. 6
Effects of PGF and VEGF inhibition on their transcription and secretion in phagocytes. a Representative images of in situ hybridization (ISH) in single laser spots of RPE/choroidal flat mounts 7 days after laser damage. Probes bind specifically to mRNAs of PGF and VEGF. Scale bar: 100 μm. b Mean RNA expression of VEGF per laser spot in RPE/choroidal flat mounts 7 days after laser coagulation. Expression was determined by quantifying the mean colored pixels per area (n = 10 laser spots for IgG, n = 10 laser spots for aVEGF, n = 11 laser spots for aPGF, n = 10 laser spots for aVEGF/aPGF, n = 14 laser spots for aflibercept). c Mean RNA expression of PGF per laser spot in RPE/choroidal flat mounts 7 days after laser coagulation. Expression was determined by quantifying the mean colored pixels per area (n = 10 laser spots for IgG, n = 10 laser spots for aVEGF, n = 11 laser spots for aPGF, n = 10 laser spots for aVEGF/aPGF, n = 14 laser spots for aflibercept). d Cytokine levels of VEGF in RPE/choroidal flat mounts 7 days after laser damage measured by ELISA (n = 6 flat mounts per group). e Cytokine levels of PGF in RPE/choroidal flat mounts 7 days after laser damage measured by ELISA (n = 6 flat mounts per group). Data are shown as mean ± SEM (*P < 0.05, **P < 0.01, ***P < 0.001)

References

    1. Wong WL, Su X, Li X, Cheung CM, Klein R, Cheng CY, Wong TY. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2014;2:e106–e116. doi: 10.1016/S2214-109X(13)70145-1. - DOI - PubMed
    1. Nguyen CL, Oh LJ, Wong E, Wei J, Chilov M. Anti-vascular endothelial growth factor for neovascular age-related macular degeneration: a meta-analysis of randomized controlled trials. BMC Ophthalmol. 2018;18:130. doi: 10.1186/s12886-018-0785-3. - DOI - PMC - PubMed
    1. Yang S, Zhao J, Sun X. Resistance to anti-VEGF therapy in neovascular age-related macular degeneration: a comprehensive review. Drug Des Devel Ther. 2016;10:1857–1867. doi: 10.2147/DDDT.S115121. - DOI - PMC - PubMed
    1. Chen M, Xu H. Parainflammation, chronic inflammation, and age-related macular degeneration. J Leukoc Biol. 2015;98:713–725. doi: 10.1189/jlb.3RI0615-239R. - DOI - PMC - PubMed
    1. Wang X, Zhao L, Zhang J, Fariss RN, Ma W, Kretschmer F, Wang M, Qian HH, Badea TC, Diamond JS, et al. Requirement for microglia for the maintenance of synaptic function and integrity in the mature retina. J Neurosci. 2016;36:2827–2842. doi: 10.1523/JNEUROSCI.3575-15.2016. - DOI - PMC - PubMed

MeSH terms

Grants and funding